Navigation Links
IR BioSciences Announces Promising Data from Study of Its Compound,Homspera

= "mailto:jreynolds@ceocast.com">jreynolds@ceocast.com blane@immuneregen.com

CONTACT: MEDIA: W. Jason Grimley of Spelling Communications,+1-310-477-9500, ; INVESTORS: Josh Reynolds ofCEOcast, Inc., +1-212-732-4300, ; or IN-HOUSE INVESTORCONTACT: Bill Lane of ImmuneRegen BioSciences, Inc., +1-480-922-3926, jgrimley@spellcom.com jreynolds@ceocast.com blane@immuneregen.com

Web site: http://www.immuneregen.com/

Ticker Symbol: (NASDAQ-OTCBB:IRBO)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 52397 1Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 52397 2Biomodels Expands Efforts in Cancer Supportive Care Pulmonary Fibrosis 3B Preclinical Research Organization Names Dr Stephen T Sonis as Partner 13146 1Biomodels Expands Efforts in Cancer Supportive Care Pulmonary Fibrosis 3B Preclinical Research Organization Names Dr Stephen T Sonis as Partner 13146 2Is somatic hypersensitivity a predictor of irritable bowel syndrome 3F 52394 1Is somatic hypersensitivity a predictor of irritable bowel syndrome 3F 52394 2